The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: Results of a phase Ib dose-escalation, open-label study

L. R. Molife, P. C. Fong, L. Paccagnella, A. H.M. Reid, H. M. Shaw, L. Vidal, H. T. Arkenau, V. Karavasilis, T. A. Yap, D. Olmos, J. Spicer, S. Postel-Vinay, D. Yin, A. Lipton, L. Demers, K. Leitzel, A. Gualberto, J. S. De Bono

Research output: Contribution to journal › Article › peer-review

82 Scopus citations

Fingerprint

Dive into the research topics of 'The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: Results of a phase Ib dose-escalation, open-label study'. Together they form a unique fingerprint.

Medicine & Life Sciences